Latest Breaking News On - Pharma limited nasdaq - Page 4 : comparemela.com

OKYO Pharma (OKYO) to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain ("NCP") Following Announcement of Clinical Trial Agreement with Tufts Medical Center

OKYO Pharma Limited (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”) to address the significant unmet need in this multi-billion-dollar market, is pleased to announce a new agreement with Tufts Medical Center to conduct a 40-patient .

OKYO Pharma Announces Proposed Public Offering of Ordinary

LONDON and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused.

OKYO Pharma Limited Receives Nasdaq Deficiency Notice

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) OKYO Pharma Limited (Nasdaq: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical.

OKYO Pharma Announces Proposed Public Offering of Ordinary Shares

LONDON and NEW YORK, July 28, 2023 OKYO Pharma Limited , an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant.